CURRICULUM VITAE
Andrew Freese, M.D., Ph.D.
Personal:
Born: Boston, MA on July 4, 1959
Home Address: 1172 Meredith Lane, Chester Springs, PA 19425
Work Address: Brandywine Valley Neurosurgery and Spine, 213 Reeceville Rd, Suite 33,
Coatesville, PA 19320; 760 West Lincoln Highway, Exton, PA 19341
Email Address: afreese@pa-spine.com
Present Positions:
Neurosurgical Medical Director, 2008-current, Brandywine Hospital, Coatesville, PA
Chief of Neurosurgery, Brandywine Valley Neurosurgery and Spine, 2008-current, Coatesville, PA
Executive Director, The CNS Gene Therapy Consortium, 1803 Pine St., Suite 1-F,
Philadelphia, PA 19103
Senior Research Fellow, Cell and Gene Therapy Center, Robert Wood Johnson Medical
School, Camden, N.J.;
CEO and President, Freese Technology Enabling Corporation (Freese TEC), 40 Morris Ave,
Suite 120, Bryn Mawr, PA 19010
Education:
Neurosurgery Residency/Fellowship, 1991-1997: University of Pennsylvania, Philadelphia, PA
Surgical Internship, 1990-1991: University of Pennsylvania, Philadelphia, PA
Ph.D., 1992: Massachusetts Institute of Technology, Cambridge, MA; Division of Health
Sciences and Technology (HST), Program in Applied Biology in Medicine
M.D., 1990: Harvard Medical School, Boston, MA; Health Sciences and Technology with
Honors Thesis
B.A., 1981: Harvard University, Cambridge, MA, Biochemistry (Magna Cum Laude with High
Honors Thesis).
Professional Associations:
American Medical Association (AMA); American Association for the Advancement of Science
(AAAS); Sigma Xi Academic Honorary Society (MIT Chapter); Society for Neuroscience;
International Brain Research Organization; New York Academy of Sciences; Pennsylvania
Medical Association; Chester County Medical Society; Pennsylvania Neurosurgical Society;
American Association of Neurological Surgeons; Congress of Neurological Surgeons; The CNS
Gene Therapy Consortium; American Society for Gene Therapy; North American Spine Society
1
Licensure and Accreditation:
M.D. Licences, States of Pennsylvania, Minnesota and South Carolina (active);
United States Drug Enforcement Agency (DEA) Controlled Substances License;
Diplomate, National Board of Medical Examiners (USA), 1990;
Board Certification, American Board of Neurological Surgeons, 2002-present; recertification
2012-2022.
Honors and Awards:
Harvard University Scholarships 1978-1981; Dean's List 1978-1981; High Honors Thesis
(Biochemistry), Harvard University, 1981; Sigma Xi (MIT); Medical Scientist Training
Program M.D., Ph.D. Fellowship, 1986-1990; M.D. Honors Thesis, Harvard Medical School,
1990; Nemir Research Foundation Award, 1993; DeHillebranth Foundation Research Award,
1994; American Men and Women of Science, 1994; Who's Who in Healthcare and Medicine,
1997-2007; Who's Who in Science and Engineering, 1998-2007; Who's Who in America, 19982007; Strawbridge Research Fund Award, 1999-2000; Physician/Scientist of the Year Award,
Canavan Foundation, Illinois, 2004; Main Line Today ‘Top Doc’ Neurosurgeon in the
Philadelphia region, 2008-2012; Health Grades Recognized Physician; Vitals Compassionate
Doctor Recognition 2010-2013; Vitals Patients’ Choice Award, 2012- 2013; Vitals Top 10
Doctor-State (Pennsylvania, Neurological Surgeon), 2014; Vitals Top 10 Doctor-Metro Area
(Delaware Valley, Neurological Surgeon), 2014.
Additional Skills and Previous Work Experience:
2014-2015: Director of Cervical Spine Advisory Group, Medicrea, Neyron, France
2012-2015: Consultant, Medicrea, Neyron, France
2010-2013: Member of Surgeon Advisory Board, Lanx, Broomfield, CO
2008-2012: Consultant, Globus Spine, Audobon, PA
2006-2012: Consultant, Synthes Spine, West Chester, PA
2006-2007: Chairman of Neurosurgery and Director of Translational Neurosciences, University
of South Carolina,
2004-2006: Professor and Vice Chairman, Department of Neurosurgery and Director of Spinal
Neurosurgery, University of Minnesota Medical School;
2005-2006: Co-Director, The University of Minnesota Comprehensive Spine Center;
2004-2006: Director, Laboratory of Molecular Neurosurgery, University of Minnesota;
2004-2006: Senior Member, Graduate Program in Neuroscience, University of Minnesota;
2003-2004: Professor of Neurosurgery, Drexel Univ. College of Medicine,
2003-2004: Director of the Graduate Spine Center, Graduate Hospital of the Drexel University
College of Medicine;
2000-2003: Vice Chairman of Neurosurgery, Thomas Jefferson University,
1997-2003: Director of Neurosurgery Research, Thomas Jefferson University,
1997-2003: Associate Professor of Neurosurgery, Thomas Jefferson University,
1997-2002: Associate Director, CNS Gene Therapy Center, Thomas Jefferson University,
1999-2003: Clinical Mentor, Rothman Institute and Neurosurgery Spine Fellowship
Programs, Thomas Jefferson University
1997-1999: Co-Founder and Treasurer, Medagen, Inc., 400 Hamilton Ave., Palo Alto, CA
94301 – restructured as Neurologix, Inc., New York, NY
1997: Visiting Fellow, Division of Functional Neurosurgery; University of Toronto.
2
Additional Skills and Previous Work Experience, continued:
1996-1997: Clinical Instructor and Chief Resident, Dept. Neurosurgery, University of
Pennsylvania,
1994-1997: Director, Laboratory of Molecular Neurosurgery, The Graduate Hospital of the
University of Pennsylvania,
1994-1997: Member, Institute for Human Gene Therapy, University of Pennsylvania.
1995-1997: Member, Wistar Institute Glioma Group
1995:
Spinal Surgery and Instrumentation Elective Fellowship, Hospital of the University
of Pennsylvania, Philadelphia, PA (6 months).
1994-1995: Visiting Scientist, Wistar Institute, Philadelphia, PA.
1993-1995: Scientific Consultant, Polykinetix, Inc., New York, NY.
1993:
Surgical Epilepsy Fellowship, Graduate Hospital/University of Pennsylvania
Comprehensive Epilepsy Program, Philadelphia, PA (6 months).
1991-1993: Junior Resident, Division of Neurosurgery, Hospital of the University of
Pennsylvania,
1990-1991: Surgical Intern, Department of Surgery, Hospital of the University of Pennsylvania,
1989-1990: Scientific Director, Neurel, Inc., Boston, MA.
1987-1989: President and Co-Founder, Neurel, Inc., Boston, MA.
1985-1986: Teaching Fellow for Basic Neuroscience Course, Harvard Medical School, Boston,
MA.
1983: Research Assistant, Laboratory of Molecular Biology, NINCDS, NIH, Bethesda, MD.
1981: Summer Research Assistant, Dept. of Medicine, Mass. General Hospital, Boston, MA.
1980: Staff Assistant, National Academy of Sciences, Washington, D.C.
1979: Research Assistant, Laboratory of Dev. and Metabolic Neurology, NIH, Bethesda, MD.
 Plenary Speaker, Synthes Annual Meeting, Hollywood, FL, May, 2005
 Cervical Spine Think Tank, Synthes Spine, Boston, Sept, 2003
 Think Tank for Biological Approaches to Spinal Disorders, Medtronic/Sofamor Danek
Amelia Island, Florida, May, 2001 and May, 2002
 NIH Grant Review Committee, NINDS, RFA-NS-02-007 for Gene Therapy of Neurological
Disorders; March, 2002
 Peer Review Panel on Department of Defense Congressionally Directed Medical Research
Program on Defense and Veterans Head Injury Program (USAMRMC), October, 2000
 Grant Reviewer, American Institute of Biological Sciences, July, 2000
 Peer Review Panel on Neurotoxin Exposure for US Army Medical Research and Material
Command (USAMRMC), September, 1998
 Developed Residency brochure and Website for Department of Neurosurgery, Thomas
Jefferson University
 Invited Guest Editor for Experimental Neurology, March, 1997 issue
 Organized International Conference on Gene Therapy for CNS Disorders, sponsored by
the University of Pennsylvania, held June 8-10, 1995, Philadelphia, PA
 Co-Founder and Executive Director of The Parkinson's Disease Gene Therapy Consortium,
an international organization of approximately 60 scientists and clinicians dedicated to
evaluating gene therapy and related approaches to Parkinson's Disease--first meeting held
April 11- 13, 1996; renamed The CNS Gene Therapy Consortium
3



Ad-hoc Reviewer: Proceedings of the National Academy of Sciences, Journal of Controlled
Release, Brain Research, Biomaterials, Human Gene Therapy, Neurosurgery, and
Experimental Neurology
Referee for Marsden Fund; New Zealand Foundation for Research, Science and Technology
Member, Board of Directors, Canavan Disease Research Foundation
Established Collaborative Research Programs:
 Performed first AAV (adeno-associated virus) gene transfer into the human brain in a FDA
approved clinical trial.
 Gene therapy approaches to Parkinson's Disease, introducing genes encoding
neurotransmitter biosynthetic enzymes and neurotrophic factors into the CNS.
 Development of novel instrumentation and navigation systems for spinal surgery
 Gene therapy for pituitary adenomas and malignant brain tumors.
 Analysis of polymeric and liposomal drug delivery devices for application to Neurosurgical
and Spine disorders.
 Gene and Cellular Therapy of Spinal Degenerative Disease
 Gene therapy of neurometabolic diseases (including Canavan Disease)
 Clinical and radiological evaluation of spinal instrumentation and fusion procedures.
Funded Grants:
1) Treatment of Glioma, PAR-02-139, NINDS Cooperative Program in Translational Research
Direct Costs: $492,608 (Principal Investigator for UMN U01 portion), September, 2006August, 2011; funded
2) Stem Cells for CNS Therapies in MPS Type 1, NIH/NINDS funded grant, 2006-2009,
Direct Costs: $1,250,000 (Co-Investigator)
3) Research Grant to the CNS Gene Therapy Consortium for Gene therapy of Spine Disorders;
Direct Costs $150,000 (Principal Investigator, October, 2005-May, 2007)
4) Development of Conference on Gene and Cellular Therapy for Spine Disorders. Synthes
Spine, Inc., Direct Costs: $85,000 (Principal Investigator, November, 2003-October, 2004)
5) Development of Gene and Cellular Therapy for Spine Disorders. Synthes Spine, Inc., Direct
Costs: $65,000 (Principal Investigator, October, 2002-October, 2003)
6) Aspartoacylase Gene Transfer in brain/Canavan Disease, RO1 NS42120-1, NIH/NINDS
Pilot Clinical Grant, Total Costs: $583,258 (principal clinical investigator, 2001-2003,
extension to 2007)
7) Towards Gene Therapy of Parkinson's Disease. NIH-RO1 NS 39144 Direct Costs: $756,000
(co-investigator, 1999-2002)
8) Development of gene therapy approaches to Parkinson's Disease. Progen, Inc. Direct
Costs: $80,000 (Principal Investigator, 2000)
9) Gene Therapy of Canavan Disease. Strawbridge Research Fund, Direct Costs: $150,000
(Principal Investigator, 1999-2000)
4
Publications:
Original Articles, Reviews, and Letters:
Freese, A., Brady, R.O., Gal, A.E. (1980): A ß-Glucosidase in Feline Kidney that
Hydrolyzes Amygdalin (Laetrile). Archives of Biochemistry and Biophysics, 201(2):
363-368.
Liscovitch, M., Freese, A., Blusztain, J.K., Wurtman, R.J. (1985): High Performance
Liquid Chromatography of Water-Soluble Choline Metabolites. Analytical
Biochemistry, 151:182-187.
Liscovitch, M., Freese, A., Blusztajn, J.K., Wurtman, R.J. (1986): Phosphatidylcholine
Biosynthesis in the Neuroblastoma-Glioma Hybrid Cell Line NG108-15: Stimulation by
Phorbol Esters. Journal of Neurochemistry, 47(6): 1936-1941.
Blusztajn, J.K., Liscovitch, M., Freese, A., Wurtman, R.J. (1987): Stimulation of Choline
Release from NG108-15 Cells by 12-0-tetradecanoylphorbol 13-acetate. Biochemical
Journal, 241:81-86.
Freese, A., Swartz, K.J., During, M.J. (1988): Branched Chain Amino Acids in
Amyotrophic Lateral Sclerosis. The Lancet, 8612:680-682.
During, M.J., Freese, A. (1988): L-Tryptophan, a Natural but not Necessarily Safe
Antidepressant. Australian and New Zealand Journal of Psychiatry, 22:339.
Freese, A., Swartz, K.J., During, M.J. (1988): Potential Neurotoxicity of Tryptophan.
Annals of Internal Medicine, 108(2):312-313.
Freese, A. (1988): Excitotoxic Models of Huntington's Disease. Proceedings of the MIT
Health Sciences and Technology Forum, 2:53-59.
Freese, A., Sabel, B.A., Saltzman, W.M., During, M.J., and Langer, R. (1989): Controlled
Release of Catecholamines from a Polymeric Brain Implant: In Vitro Characterization.
Experimental Neurology, 103:234-238.
During, M.J., Freese, A, Sabel, B.A., Deutch, A., Roth, R.E., Langer, R. (1989): Controlled
Release of Catecholamines from a Polymeric Brain Implant: In Vivo Characterization.
Annals of Neurology, 25:351-356.
During, M.J., Heyes, M.P., Freese, A., Markey, S.P., Martin, J.B., Roth, R.H. (1989):
Quinolinic Acid Concentrations in Striatal Extracellular Fluid Reach Potentially
Neurotoxic Levels Following Systemic L-Tryptophan Loading. Brain Research,
476:384-387.
During, M.J., Freese, A., Heyes, M.P., Swartz, K.J., Markey, S., Roth, R.H., Martin, J.B
(1989): Neuroactive Metabolites of L-Tryptophan, Serotonin and Quinolinic Acid, in
Striatal Extracellular Fluid: Effect of Tryptophan Loading. FEBS Letters, 247:438-444.
Geller, A.I., Freese, A. (1989): An HSV- 1 Vector System to Transfer Genes into Neurons
in the Adult Rat Brain. Experimental Medicine,7:81-93.
Freese, A., Swartz, K.J., During, M.J., Martin, J.B. (1990): Kynurenine Metabolites of
Tryptophan: Implications for Neurological Disease. Neurology, 40:691-695.
Geller, A.I., Freese, A. (1990): Transfection of Cultured Central Nervous System Neurons
with a Defective HSV-1 Vector which Stably Expresses ß-Galactosidase. Proceedings
of the National Academy of Sciences, USA, 87:1149-1153.
5
Publications, continued:
Original Articles, Reviews, and Letters, continued:
Freese, A., Neve, R., Geller, A.I. (1990): HSV-1 Vector Mediated Neuronal Gene Delivery:
Strategies for Molecular Neuroscience and Neurology. Biochemical Pharmacology,
40:2189-2199.
Freese, A., DiFiglia, M., Beal, M.F., Martin, J.B. (1990): Characterization and Mechanism
of Glutamate Toxicity in Primary Striatal Cultures. Brain Research, 521:254-264.
Koroshetz, W.J., Freese, A., DiFiglia, M. (1990): Correlation between Excitatory Amino
Acid Induced Current Responses and Excitotoxicity in Striatal Cultures. Brain
Research, 521:265-272.
Freese, A., Finn, S.F., During, M.J. (1990): Eosinophilia Myalgia Syndrome, Tryptophan
and Quinolinic Acid. Annals of Internal Medicine, 112:795.
Sabel, B.A., Dominiak, P., Hauser, W., During, M.J., Freese, A. (1990): Extended
Levodopa Release from a Subcutaneously Implanted Polymer Matrix in Rats. Annals of
Neurology, 28:714-717.
Sabel, B.A., Dominiak, P., Hauser, W., During, M.J., Freese, A. (1990): Levodopa Delivery
from a Controlled-Release Polymer Matrix: Delivery of More than 600 Days and 225
Days of Elevated Plasma Levels after Subcutaneous Implantation in Rats. The Journal
of Pharmacology and Experimental Therapeutics, 255:914-922.
Swartz, K.J., During, M.J., Freese, A., Beal, M.F. (1990): Cerebral Synthesis and Release
of Kynurenic Acid: An Endogenous Antagonist of Excitatory Amino Acid Receptors.
The Journal of Neuroscience, 10:2965-2973.
During, M.J., Heyes, M.P., Freese, A., Swartz, K.J., Matson, W.R., Markey, S.P., Martin,
J.B., Roth, R.H. (1991): Indolic and Kynurenine Pathway Metabolites of Tryptophan in
Rat Brain: Effect of Precursor Availability on In Vivo Release. Advances in
Experimental and Medical Biology, 294:535-539.
Freese, A., Geller, A.I. (1991): Infection of Cultured Striatal Neurons with a Defective
HSV-1 Vector: Implications for Gene Therapy. Nucleic Acids Research, 19:7219-7223.
During, M.J., Freese, A., Deutch, A.Y., Kibat, P., Sabel, B.A., Langer, R., Roth, R.H.
(1992): Biochemical and Behavioral Recovery in a Rodent Model of Parkinson's
Disease following Stereotactic Implantation of Dopamine-containing Liposomes.
Experimental Neurology, 115:193-199.
Freese, A., Finklestein, S., and DiFiglia, M. (1992): Basic Fibroblast Growth Factor
Protects Striatal Neurons In Vitro from NMDA Receptor Mediated Excitotoxicity. Brain
Research, 575:351-355.
Geller, A.I., During, M.J., Haycock, J.W., Freese, A., Neve, R. (1993): Long-term increases
in Neurotransmitter Release from Neuronal Cells Expressing a Constitutively Active
Adenylate Cyclase from a Herpes Simplex Virus 'I'ype I Vector. Proceedings of the
National Academy of Sciences, USA, 90:7603-7607.
Jans, A., Galetta, S.L., Freese, A., Raps, E.C., Curtis, M., Grossman, R.I., Gomori, J.M.,
Duhaime, A.C. (1993): Superficial Siderosis of the Central Nervous System: MRI and
Pathologic Correlation. Journal of Neurosurgery, 79:756-760.
Freese, A., O'Rourke, D., Judy, K., O'Connor, M.J. (1994): Application of
5-Bromodeoxyuridine to Neurosurgery, Journal of Neuro-Oncology, 20:81-95.
Geller, A.I., During, M.J., Oh, Y.J., Freese, A., O'Malley, K. (1995): A HSV-1 Vector
Expressing Tyrosine Hydroxylase Causes Production and Release of L-DOPA and Dopamine
from Cultured Rat Striatal Neurons. Journal of Neurochemistry, 64:487-496.
6
Publications, continued:
Original Articles, Reviews, and letters, continued:
O'Connor, W.M., Masukawa, L.M., Freese, A., Sperling, M.R., French, J.A., O'Connor, M.J.
(1996): Hippocampal Cell Distributions in Temporal Lobe Epilepsy: A Comparison between
Patients With and Without an Early Risk Factor, Epilepsia, 37(5): 440-449.
Freese, A., During, M.J., Davidson, B., Kaplitt, M.G., Flamm, E.S., Gennarelli, T.A.,
Snyder, P.J. (1996): Modulation of Prolactin Secretion from Human Lactotroph
Adenoma Cells with an Adenovirus Vector containing the Tyrosine Hydroxylase Gene,
Journal of Clinical Endocrinology and Metabolism, 81(6):2401-2404.
Freese, A., Stern, M., Kaplitt, M.G., O'Connor, W.M., Abbey, M.V., O'Connor, M.J.,
During, M.J. (1996): Prospects for Gene Therapy in Parkinson's Disease, Movement
Disorders, 11(5):469-488.
Stern, M.B., Freese, A. (1996): Gene Therapies and Parkinson's Disease. Parkinson
Report, 17(2):13-14.
Schnee, C.L., Freese, A., Ansell, L.V. (1997): Outcome Analysis of Adults with
Spondylolisthesis Treated with Posterolateral Fusion and Transpedicular Screw
Fixation. Journal of Neurosurgery, 86:56-63.
Dibbern, D.A., Loevner, L.A., Lexa, F.J., Lieberman, A.P., Salhany, K.E., Freese, A.,
Marcotte, P. (1997): Thoracic Cord Compression Due to Extramedullary Hematopoeisis
in Myelodysplastic Syndrome: Findings on MRI Examination. American Journal of
Neuroradiology, 18:363-366.
Stern, M.B., Freese, A. (1997): Parkinson's Disease: The Case for Novel Treatment
Strategies. Experimental Neurology, 144:2-4.
Freese, A., During, M.J., O'Connor, W.M., Langer, D., O'Connor, M.J., Kaplitt, M.G.
(1997): Direct Gene Transfer into Human Epileptogenic Hippocampus tissue with an
Adeno-associated Virus Vector, Epilepsia, 38(7): 759-766.
Schnee, C.L., Freese, A., Weil, R.J., Marcotte, P.J. (1997): Anterior Cervical
Reconstruction using Iliac Crest Autograft: Harvest Complications and Graft Outcomes,
Spine, 22(19):2222-2227.
O'Connor, W.M., Davidson, B., Kaplitt, M.G., O'Connor, M.J., Langer, D., During, M.J.,
Freese, A. (1997): Adenovirus Vector Mediated Gene Transfer into Human
Epileptogenic Brain Slices: Prospects for Gene Therapy in Epilepsy, Experimental
Neurology, 148:167-178.
During, M.J., Samulski, R.J., Elsworth, J.D., Kaplitt, M.G., Leone, P., Xiao, X., Li, J.,
Freese, A., Roth, R.H., Sladek, J.R., O'Malley, K.L., Redmond, D.E. (1998): In Vivo
Expression of Therapeutic Human Genes for Dopamine Production in the Caudates of
MPTP-Treated Monkeys Using an AAV Vector, Gene Therapy, 5: 820-827.
Freese, A. (1999): Restorative Gene Therapy Approaches to Parkinson's Disease, Medical
Clinics of North America, 83:537-48.
Freese, A., Simeone, F.A. (1999): Treatment of Neurosurgical Disease in the New
Millenium, Ophthalmology Clinics of North America, 12(4):533-537.
Leone, P., McPhee, S.W., Janson, C.G., Liu, C., Silver, D., Davidson, B.L., Freese, A.,
During, M.J. (2000): Multi-site Partitioned Delivery of Human Tyrosine Hydroxylase
Gene with Phenotypic Recovery in Parkinsonian rats, Neuroreport, 11(6):1145-51.
Publications, continued:
7
Original Articles, Reviews, and letters, continued:
Leone, P., Janson, C.G., Bilianuk L., Wang, J., Sorgi, F., McPhee, S.W., Haung, L.,
Matalon, R., Kaul, R., Freese, A., Young, D., Xu, R., Mee, E., During, M.J. (2000):
Apartoacylase Gene Transfer to the Mammalian Nervous System with Therapeutic
Implications for Canavan Disease, Annals of Neurology, 48:27-38.
Janson, C.G., McPhee, S., Leone, P., Freese, A., During, M.J. (2001): Recombinant ViralBased Gene Transfer to the Mammalian CNS for Functional Genomic Studies, Trends
in Neuroscience, 24(12): 706-712.
Janson, C.G., McPhee, S., Bilaniuk, L., Haselgrove, J., Testaiuti, M., Freese, A., Wang, DJ., Shera, D., Hurh, P., Rupin, J., Saslow, E., Goldfarb, O., Goldberg, M., Larijani, G.,
Sharrar, W., Liouterman, L., Camp, A., Kolodny, E., Samulski, R.J., Leone, P. (2002):
Gene Therapy of Canavan Disease: AAV-2 Vector for Neurosurgical Delivery of
Aspartoacylase Gene (ASPA) to the Human Brain, Human Gene Therapy, 13:13911412.
Janson C.G., Leone, P., Freese, A. (2002): Parkinson’s Disease: Molecular Pathology,
Science and Medicine, 8:328-337.
Janson C.G., Leone, P., Freese, A. (2003): Parkinson’s Disease: Cellular Basis of Medical
Treatment, Science and Medicine, 9:24-35.
Janson C.G., Leone, P., Freese, A. (2003): Parkinson’s Disease: Surgical and Emerging
Therapies, Science and Medicine, 9:82-95
Harrop, J.S., Poulsen, D., Xiao W., Freese, A., During, M.J. (2004): Effect of Altering
Titer, Serotype, and Promoter in Recombinant Adenoassociated Virus Gene Therapy
Expression of Spinal Cord Neurons and Astrocytes. Spine, 29(24):2787-2792.
McPhee, S., Francis, J., Janson, C.G., Serikawa, T., Hyland, K., Ong, E., Raghavan, S.,
Young, D., During, M.J., Freese, A., Leone, P. (2005): Effects of AAV-2 mediated
aspartoacylase gene transfer in the tremor rat model of Canavan Disease, Molecular
Brain Research, 135(1-2):112-121.
Freese, A., Janson, C., Leone, P., Simeone, F.A. (2005): Introduction to Principles of
Molecular Neurosurgery, Prog. Neurol. Surg. 18:1-4.
Ohlfest, J., Demorest, Z., Motooka, Y., Oh, S., Chen, E., Scappaticci, F., Ekker, S., Low,
W., Freese, A., Largaespada, D. (2005): Combinatorial Antiangiogenic Gene Therapy
by Nonviral Gene Transfer Using the Sleeping Beauty Transposon Causes Tumor
Regression and Improves Survival in Mice Bearing Intracranial Human Glioblastoma,
Molecular Therapy, 12(5):778-788.
McPhee, S., Francis, J., Janson, C.G., Serikawa, T., Hyland, K., Ong, E., Raghavan, S.,
Young, D., During, M.J., Freese, A. , Leone, P. (2005): Effects of AAV-2 mediated
aspartoacylase gene transfer in the tremor rat model of Canavan Disease, Mol. Brain
Res., 135:112-121.
Wiesner, S.M., Freese, A., Ohlfest, J.R. (2005): Emerging Concepts in Glioma Biology:
Implications for Clinical Protocols and Rational Treatment Strategies. Neurosurg. Foc.
19(4): 1-6.
Ohlfest, J., Freese, A., Largaespada, D. (2005): Nonviral Vectors for Cancer Gene
Therapy, Current Gene Therapy. 5(6):629-641.
Publications, continued:
8
Original Articles, Reviews, and letters, continued:
Ohlfest, J., Oh, W., Demorest, Z.L., Motooka, Y., Lobitz, P.D., Low, W.C., Largaespada,
D.A., Freese, A. (2006): The Sleeping Beauty Transposon Facilitates Sustained Gene
Transfer and Expression in Neural Progenitor-like Cells in the Adult Mouse Brain,
Molecular Therapy
McPhee, S., Janson, C., Li, C., Samulski, R.J., Camp, A., Shera, F., Lioutermann, L., Feely,
M., Freese, A., Leone, P. (2006): Immune Responses to AAV in a Phase 1 Study for
Canavan Disease. J. Gene Med. 8(5):577-588.
Janson, C, Freese, A., McPhee, S., Leone, P. et al. (2006): Natural history of Canavan
disease revealed by proton magnetic resonance spectroscopy (1H-MRS) and diffusionweighted MRI. Neuropediatrics, 37(4):209-221.
Janson, C., Kolodny, E., Zeng, B-J., Raghavan, S., Pastores, G., Torres, P., Assadi, M.,
McPhee, S., Goldfarb, O., Saslow, B., Freese, A., Wang, D., Bilaniuk, L, Shera, D.,
Leone, P. (2006): Mild-onset Presentation of Canavan’s Disease Associated with Novel
G212A Point Mutation in Aspartoacylase Gene. Annals of Neurology 59(2):428-431.
Candolfi, M., Kroeger, K.M., Pluhar, G.E., Bergeron, J., Puntel, M., Curtin, J.F., McNiel,
E.A., Freese, A.B., Ohlfest, J.R., Moore, P., Lowenstein, P.R., Castro, M.G.(2007):
Adenoviral-mediated gene transfer into the canine brain in vivo, Neurosurgery;
60(1):167-178
Oh, S., Pluhar, G.E., McNeil, E.A., Kroeger, K.M., Liu, C., Castro, M.G., Lowenstein, P.R.,
Freese, A., Ohlfest, J.R. (2007): Efficacy of Nonviral Gene Transfer in the Canine
Brain. J. Neurosurg 107:136-144.
Oh, S. Odland, R., Wilson, S., Kroeger, K.M., Liu, C., Castor, M.G., Lowenstein, P.R.,
Freese, A., Hall, W.A., Ohlfest, J.R. (2007): Improved Distribution of Small Molecules
and Viral Vectors in the Murine Brain Using a Hollow Fiber Catheter. J. Neurosurg.
107(3):568-577.
Candolfi, M., Curtin, J.F., Nichols, W.S., Muhammad, G., King, G., Pluhar, G.E., McNiel,
E.A., Ohlfest, J.R., Freese, A.B., Moore, P.F., Lerner, J., Lowenstein, P., Castro, M.G.
(2007): Intracranial Glioblastoma Models in Preclinical Neuro-Oncology:
Neuropathological Characterization and Tumor Progression. J. Neurooncol. 85(2):133148.
Candolfi, M, Pluhar, G.E., Kroeger, K., Puntel, M., Curtin, J., Barcia, C., Muhamad, G.,
Xiong, W., Liu, C., Mondkar, S., Kuoy, W., Kang, T., McNeil, E.A., Freese, A.B.,
Ohlfest, J.R., Moore, P., Palmer, D., Ng, P., Young, J.D., Lowenstein, P.R., Castro,
M.G. (2007): Optimization of Adenoviral Vector-mediated Transgene Expression in the
Canine Brain In Vivo, and in Canine Glioma Cells In Vitro. Neuro-oncology 9:245258.
Leone, P., Shera, D., McPhee, S.W.J., Francis, J.S., Kolodny, E.H., Bilaniuk, L.T., Wang,
D-Y., Assadi, M., Goldfarb, O., Goldman, H.W., Freese, A., Young, D., During, M.J.,
Samulski, R.J., Janson, C.G. (2012): Long-Term Follow-Up After Gene Therapy for
Canavan Disease. Science Translational Medicine 165ra163:1-14.
Abstracts:
9
Liscovitch, M., Freese, A., Blusztajn, J.K., Wurtman, R.J. (1985): High Performance
Liquid Chromatography of Water-Soluble Choline Metabolites. Transactions of the
American Society of Neurochemistry, 16(l): 61.
Liscovitch, M., Freese, A., Blusztajn, J.K., Wurtman, R.J. (1985): Phorbol Esters Stimulate
Phosphatidylcholine Metabolism in NG108-15 Cells. Proceedings 15th Annual
Meeting, Society for Neuroscience, 11:118.5
Sabel, B.A., Freese, A., Saltzman, M., Langer, R. (1988): Long-term Controlled Release of
L-DOPA and Dopamine from a Biocompatible Polymer Matrix System: In Vitro
Characterization. Proceedings of the 9th International Symposium on Parkinson's
Disease.
During, M.J., Freese, A., Sabel, B.A., Deutch, A.Y., Langer, R., Roth, R.H. (1988):
Controlled In Vivo Release of Dopamine from a Polymeric Brain Implant. Proceedings
of the 9th International Symposium on Parkinson's Disease.
Saltzman, W.M., Freese, A., Langer, R. (1988): Design and Testing of Polymeric Brain
Implants for the Long-term Release of Dopamine and L-DOPA. Annual Meeting of the
American Institute of Chemical Engineers.
Sabel, B.A., Freese, A., During, M.J., Saltzman, M., Langer, R. (1988): Polymer Brain
Implants for Controlled Release of Dopamine: In Vitro and In Vivo Observations.
Proceedings 18th Annual Meeting, Society for Neuroscience, 14:308.9.
Sabel, B.A., Freese, A., During, M.J., Saltzman, M., Langer, R. (1988) Controlled Release
of Dopamine from a Polymeric Brain Implant: In Vitro and In Vivo Observations. 17th
Proceedings of the International Society for Developmental Neuroscience.
Freese, A., DiFiglia, M., Beal, M.F., Martin, J.B. (1988): Characterization and Mechanism
of Glutamate Neurotoxicity in Primary Striatal Cultures. Proceedings 18th Annual
Meeting, Society for Neuroscience, 14:169. 10.
During, M.J., Freese, A., Heyes, K.J., Swartz, K.J., Markey, S.P., Martin, J.B., Roth, R.
(1988): Potential Neurotoxicity of Tryptophan: Striatal Quinolinic Acid Monitored by
Microdialysis. Proceedings 18th Annual Meeting, Society for Neuroscience, 14:290.14.
Geller, A.I., Freese, A., Gusella, J.F., Breakefield, X.O. (1988): Tranfection of Neurons
with a Defective HSV-1 Vector and Expression of ß-Galactosidase. Proceedings 18th
Annual Meeting, Society for Neuroscience, 14:254.11.
Koroshetz, W.J., Freese, A., DiFiglia, M., Corey, D.P. (1988): Correlation between
Excitatory Amino Acid Induced Electrophysiological Responses and Neurotoxicity.
Proceedings 18th Annual Meeting, Society for Neuroscience, 14:169.9.
Freese, A., During, M.J. (1988): Drug Delivery for Neurological Disorders. Annual
Conference for University/Incubator Spin-Off Companies, Technology Transfer
Conferences, Boston, May 31-June 1.
Freese, A. (1988): Characterization and Mechanism of Glutamate Neurotoxicity in Primary
Striatal Cultures. 2nd Annual Health Sciences and Technology Forum, Massachusetts
Institute of Technology.
Geller, A.I., Freese, A., Gusella, J.F., Breakefield, X.O. (1988): Tranfection of Neurons
with HSV-1 Vectors: Implications for Studies on Aging. Annual Conference of the
American Society for Aging Research, June 19-21.
Geller, A.I., Freese, A., Sabel, B.A. (1989): Modification of the Rat Nigrostriatal System by
Intracerebral Injection of Defective HSV-1 Virus Vectors. Symposium on Parkinson's
Disease and Other Basal Ganglia Disorders, Bad Kissingen, April 23-25.
10
Publications, continued:
Abstracts, continued:
Sabel, B.A., Martin, C., Waldmann, C., Freese, A., Geller, A.I. (1989): Gene Transfer into
Neurons of the Adult Rat Brain. Proceedings 19th Annual Meeting, Society for
Neuroscience, 15:8:4.
Freese, A Acid Levels and Neurochemical Markers of Toxicity: Effects of Acute vs.
Chronic Tryptopha., Swartz, K.J., During, M.J., Heyes, M.P., Beal, M.F., Martin, J.B.
(1989): Regional Brain Quinolinic n Feeding. Proceedings 19th Annual Meeting,
Society for Neuroscience, 15:306:3.
Freese, A Acid Levels and Neurochemical Markers of Toxicity: Effects of Acute vs.
Chronic Tryptopha., Swartz, K.J., During, M.J., Heyes, M.P., Beal, M.F., Martin, J.B.
(1989): Regional Brain Quinolinic n Feeding. Proceedings 19th Annual Meeting,
Society for Neuroscience, 15:306:3.
During, M.J., Heyes, M.P., Freese, A., Swartz, K.J., Matson, W.R., Markey, S.P., Martin,
J.B., Roth, R.H. (1989): Indoleamine and Kynurenine Pathway Metabolites of
Tryptophan in Rat Brain. International Study Group for Tryptophan Research, p. 27.
Sabel, B.A., Freese, A., Geller, A. (1989): Transfer of a Recombinant Lac-Z Vector into
Neurons of the Adult Rat Brain: Long-term Expression without Cell Death. Annual
Meeting of the European Neuroscience Association.
Freese, A., Swartz, K.J. (1989): CNS Kynurenine Metabolites: Endogenous Agonists and
Antagonists of Glutamate Receptors. 3rd Annual Health Sciences and Technology Forum,
Massachusetts Institute of Technology.
Geller, A.I., Neve, K., Freese, A., During, M.J., Neve, R. (1990): Modification of Neuronal
Second Messenger Physiology: Expression of the Calcium Calmodulin Protein Kinase II
Gene and the Yeast Adenylate Cyclase Gene in Neurons from HSV-1 Vectors. New
York Academy of Sciences Conference on Central and Peripheral Significance of
Neuropeptide Y and its Related Peptides.
Freese, A., Finklestein, S., DiFiglia, M. (1990): Basic Fibroblast Growth Factor Attenuates
NMDA Receptor Mediated Neurotoxicity in Striatal Neurons. Proceedings 20th Annual
Meeting, Society for Neuroscience, 16.88.10.
Swartz, K.J., During, M.J., Freese, A., Beal, M.F. (1990): Cerebral Synthesis and Release
of Kynurenic Acid. Proceedings 20th Annual Meeting Society for Neuroscience,
16:88:10.
Geller, A.I., Freese, A., O'Malley, K., During, M.J., Neve, R. (1990): Stable Modification
of Rat Sympathetic Neuron Physiology and Neurotransmitter Release by Expression of
Adenylate Cyclase from a HSV- 1 Vector. Proceedings 20th Annual Meeting, Society
for Neuroscience, 16:216:5.
During, M.J., Geller, A.I., Freese, A., Neve, R. (1990): Neuronal Expression of
Parvalbumin and Calcium/Calmodulin Dependent Protein Kinase II from HSV-1
Vectors. Proceedings 20th Annual Meeting, Society for Neuroscience, 16:216.4.
Freese, A., During, M.J., O'Malley, K., Geller, A.I. (1991): Expression of Tyrosine
Hydroxylase in Striatal Cells with a HSV-1 Vector Causes Stable Production and
Regulated Release of DOPA and Dopamine: Potential Gene Therapy for Parkinson's
Disease. Proceedings 21st Annual Meeting, Society for Neuroscience, 17:424.15.
Publications, continued:
11
Abstracts, continued:
Freese, A., During, M.J., O'Malley, K., Geller, A.I. (1992): Gene Therapy with HSV- I
Vectors: Implications for Parkinson's Disease and Other Neurological Disorders.
Annual Meeting of the American Association of Neurological Surgeons, 60:1179
(Selected for Discussion).
Freese, A., During, M.J., Geller, A.I. (1993): Modulation of Neuronal Adenylate Cyclase
using HSV-1 Vectors: Implications for Neurological Disease. Annual Meeting of the
American Association of Neurological Surgeons, 61:1165.
Freese, A., Swartz, K.J., During, M.J. (1994): Pharmacological Modulation of Kynurenic
Acid, an Endogenous NMDA Receptor Antagonist: Neuroprotective Effects. Annual
Meeting of the American Association of Neurological Surgeons, 62:1296.
Freese, A., During, M.J., O'Rourke, D.M., Geller, A.I. (1994): Gene Therapy with Modified
Herpes Vectors: Implications for Molecular Neurosurgery. Annual Meeting of the
American Association of Neurological Surgeons, 62:807.
Freese, A., Hurst, R.W., Zager, E.L., Flamm, E.S. (1994): Angiographic Vasospasm
Associated with Hemorrhage from Arteriovenous Malformations. Annual Meeting of
the American Association of Neurological Surgeons, 62:1038.
Freese, A., O'Connor, M.J., Kaplitt, M.J., O'Connor, W.M., During, M.J. (1994): Adenoassociated Virus Vector Mediated Gene Transfer into Human Hippocampal Slices.
Annual Meeting of the American Epilepsy Society, 3.14.
Freese, A., Kaplitt, M.G., O'Connor, M.J., O'Connor, W.M., During, M.J. (1994): Gene
Transfer into Human Hippocampal Slices with an Adeno-associated Virus Vector. Proceedings
24th Annual Meeting, Society for Neuroscience, 592.15.
Kaplitt, M.G., Leone, P., Freese, A., Xiao, X., Pfaff, D.W., O'Malley, K.L., During, M.J.
(1994): Adeno-associated Virus (AAV) Vectors Yield Safe Delivery and Long-term
Expression of Potentially Therapeutic Genes in the Adult Mammalian Brain.
Proceedings 24th Annual Meeting, Society for Neuroscience, 602.11.
During, M.J., Kaplitt, M.G., Freese, A., Leone, P., Yiao, X., Samulski, R.J., Elsworth, J.,
Roth, R.H., Sladek, J., Jr., O'Malley, K.L., Redmond, D., Jr. (1995): In Vivo Gene
Therapy of Parkinson's Disease in a Primate Model. Annual Meeting of the American
Association of Neurological Surgeons, 63:701.
Randazzo, B.P., Freese, A., Kesari, S., Brown, S.M., MacLean, A.R., Fraser, N.W. (1995):
Treatment of Cerebral Metastases with Herpes Simplex Virus One Mutant 1716:
Culture and Animal Studies. Annual Meeting of the American Association of
Neurological Surgeons, 63:1395.
Lippman, C., Welsh, F., Kaplitt, M.G., O'Connor, W.M., During, M.J., O'Connor, M.J.,
Freese, A. (1995): Adeno-associated Virus Mediated Human Heat Shock Protein 72
Gene Transfer into Neuronal Cultures. 12th Annual Neuroscience Retreat, University of
Pennsylvania.
Freese, A., O'Connor, M.J., During, M.J., Judy, K., Davidson, B. (1995): Adenovirus
Vectors Result in Preferential Transgene Expression in Dividing Glial Cells.
International Conference on Gene Therapy for CNS Disorders, 2.12.
Publications, continued:
12
Abstracts, continued:
Lippman, C., Welsh, F., Kaplitt, M.G., Abbey, M., O'Connor, W.M., During, M.J.,
O'Connor, M.J., Freese, A. (1995): Transfer of Human Heat Shock Protein-72 into
Cultured CNS Cells using an Adeno-associated Virus Vector. International Conference
on Gene Therapy for CNS Disorders, 4. 11.
Freese, A., Langer, D., Kaplitt, M.G., O'Connor, M.J., O'Connor, W.M., During, M.J.
(1995): AAV Mediated Gene Transfer into Human Hippocampal Slices. International
Conference on Gene Therapy for CNS Disorders. 4.33.
Redmond, D.E., Jr., O'Malley, K.L., Kaplitt, M.G., Samulski, R.J., Freese, A., Elsworth,
J.D., Sladek, J.R., Jr., Leone, P., Xiao, X., Taylor, J.R., Roth, R.H., During, M.J.
(1995): AAV Vector Gene Therapies in a Primate Parkinson's Model. International
Conference on Gene Therapy for CNS Disorders, 3.10.
Langer, D.J., Barnathan, E.S., Freese, A., Welsh, F., Kariko, K. (1995): Neuronal
Protection Mediated by Heat-Shock Protein-72 Gene Delivery: A Novel T7 Polymerase
Based Gene Expression System. International Conference on Gene Therapy for CNS
Disorders, 4.12.
Lippman, C., Welsh, F., Kaplitt, M.G., O'Connor, W.M., During, M.J., O'Connor, M.J.,
Freese, A. (1995): AAV-Vector Mediated Human Hsp-72 Gene Transfer into Cultured
Cells. Proceedings 25th Annual Meeting, Society for Neuroscience, 710.9.
Freese, A., During, M.J., Kaplitt, M.G., Davidson, B.L., O'Malley, K.L., Flamm, E.S.,
Gennarelli, T.A., Snyder, P. (1995): A Novel Gene Therapy Approach to Pituitary
Adenomas. Proceedings 25th Annual Meeting, Society for Neuroscience, 838.6.
Redmond, D.E., Jr., O'Malley, K.L., Kaplitt, M.J., Samulski, R.J., Elsworth, J.D., Sladek,
J.R., Jr., Leone, P., Xiao, X., Freese, A., Taylor, J.R., Roth, R.H., During, M.J. (1995):
AAV Vectored Gene Therapy in Primate Parkinson's Model. Proceedings 25th Annual
Meeting, Society for Neuroscience, 224.22.
During, M.J., Choi-Lundberg, D., Leone, P., Lin, Q., Kaplitt, M.G., Xiao, X., Samulski,
R.J., Freese, A., Hoffer, P., Roth, R.H., Elsworth, J.D., Sladek, J.R., Jr., O'Malley, K.L.,
Federoff, H.J., Redmond, D.E., Jr., Bohn, M.C. (1995): Neuroprotection and
Neuroregeneration in Rodent and Primate Parkinson's Models Using AAV Vectors
Expressing GDNF. Proceedings 25th Annual Meeting, Society for Neuroscience, 225.9.
Freese, A., Flamm, E.S., During, M.J., Kaplitt, M.G., Davidson, B.L., O'Malley, K.,
Gennarelli, T.A., Snyder, P.J. (1995): A Novel Gene Therapy Approach to
Prolactinomas and other Pituitary Adenomas. Annual Meeting of the Congress of
Neurological Surgeons, Abstract 231.
Freese, A., O'Connor, M.J., Langer, D., Kaplitt, M.G., O'Connor, W.M., During, M.J.
(1995): Gene Transfer into Human Hippocampal tissue using an Adeno-associated
Virus Vector: Prospects for Gene Therapy in Focal Epilepsy. Annual Meeting of the
Congress of Neurological Surgeons, Abstract 748.
Lippman, C., Welsh, F., Kaplitt, M., O'Connor, W.M., During, M.J., O'Connor, M.J.,
Freese, A. (1996): Demonstration of a Direct Neuroprotective Function of Human Heat
Shock Protein-72 in Cultured CNS Neurons using an Adeno-associated Virus Vector
Expressing the Hsp-72 Gene. Annual Meeting of the American Association of
Neurological Surgeons. Abstract 1109.
13
Publications, continued:
Abstracts, continued:
Freese, A., Leone P., Choi-Lundberg D., Federoff, H.J., Redmond, D.E., During, M.J. (1996):
A Gene Therapy Approach to Parkinson's Disease Using an AAV Vector Expressing Glial
Derived Neurotrophic Factor (GDNF). Annual Meeting of the American Association of
Neurological Surgeons, Abstract 1320.
Freese, A., During, M.J., Lowen, G., O'Connor, W.M., O'Connor, M.J., Davidson, B.L.
(1996): Adenovirus Vector-Mediated Delivery of the Tyrosine Hydroxylase Gene into
Striatal Cells: Implications for Gene Therapy in Parkinson's Disease. Annual Meeting
of the American Association of Neurological Surgeons, Abstract 742.
Schnee, CL, Freese, A., Weil, R.J., Marcotte, P.J. (1996): Morbidity and Fusion Outcome
of Autologous Iliac Crest Bone Graft for Anterior Cervical Reconstruction. Annual
Meeting of the Congress of Neurological Surgeons, Abstract 739.
Schnee, C.L. Weil, R.J., Freese, A., Marcotte, P.J. (1996): Evaluation of Operative
Technique for Thoracolumbar Spinal Neoplasms. Annual Meeting of the Congress of
Neurological Surgeons, Abstract 275.
Freese, A. (1997): A Historical Perspective on Gene Therapy: Implications for Molecular
Neurosurgery. Annual Meeting of the American Association of Neurological Surgeons,
Abstract 839.
Abbey, M., Davidson, B.L., Cox, R., Hurst, R., Langer, D., Riina, H., O'Connor, M.J.,
Freese, A. (1997): Nitric Oxide Synthase Gene Transfer into Human Cerebral Vascular
Smooth Muscle Cells: Prospects for Genetic Intervention in Vasospasm. Annual
Meeting of the American Association of Neurological Surgeons, Abstract 1036.
Freese, A., Figuereo, S., Wilensky, R., During, M.J., Riina, H., O'Connor, M.J., Hurst, R.J.
(1997): Selective Endovascular Delivery of Gene Transfer Systems into the Brain:
Prospects for Targeting of Gene Therapy in Neurological Disorders. Annual Meeting of
the American Association of Neurological Surgeons, Abstract 1219.
Weil, R.J., Schnee, C., Freese, A., Marcotte, P.J. (1997): Anterior Cervical Decompression
and Fusion for Cervical Spondylotic Myelopathy, Annual Meeting of the American
Association of Neurological Surgeons, Abstract 1350.
O'Connor, W.M., Davidson, B.L., Kaplitt, M.G., Abbey, M.V., During, M.J., Leone, P.,
Langer, D., O'Connor, M.J., Freese, A. (1997): Adenovirus Vector Mediated Gene
Transfer into Human Epileptogenic Brain Slices. 22nd International Epilepsy Congress
Proceedings, (in Epilepsia: 38:203).
Freese, A., Young, D.D., Liu, C.Y., Leone, P., Davidson, B.L., Silver, D., Xie, H., During,
M.J. (1997): Phenotypic Recovery in Parkinsonian Rats: Relationship Between numbers
of Transduced Cells and Behavior Using an Adenoviral Vector Expressing Tyrosine
Hydroxylase. Proceedings 27th Annual Meeting, Society for Neuroscience, Abstract
211.3
During, M.J., Nass, D.J., Xie, H., Freese, A., Leone, P. (1997): Towards Gene Therapy of
Epilepsy: Comparison of GAD-65, GABA-A Delta Subunit, and GDNF Vectors in a
Rat kainate model. Proceedings 27th Annual Meeting, Society for Neuroscience,
Abstract 319.8.
14
Publications, continued:
Abstracts, continued:
O'Connor, M.J., Weil, R.J., Liporace, J., Freese, A., Sperling, M.R. (1998): Multiple
Subpial Transactions in Eloquent Cortex. Annual Meeting of the American Association
of Neurological Surgeons, Abstract 1289.
O'Connor, M.J., Sperling, M.R., Liporace, J., Sirven J., Barry, E., Freese, A. (1998):
Results of Long Term Follow up of 405 Temporal Lobectomies over a Twenty Year
Period. Annual Meeting of the American Association of Neurological Surgeons,
Abstract 714.
Freese, A., O'Connor, M.J., Leone, P., Ness, D.J., Xie, H., During, M.J. (1998): Genetic
Intervention in an Animal Model of Epilepsy: Effects of Transfer of Genes Encoding
Glutamic Acid Decarboxylase, a GABA Receptor Subunit, or Glial Cell-derived
Neurotrophic Factor. Annual Meeting of the American Association of Neurological
Surgeons, Abstract 1263.
Freese, A., Young, D.D., Silver, D., Liu, C.Y., Davidson, B.L., O'Connor, M.J., Leone, P.,
During, M.J. (1998): Correlation Between Number of Transduced Cells and Behavioral
Recovery in a Rat Parkinson's Disease Model Following In Vivo Gene Therapy. Annual
Meeting of the American Association of Neurological Surgeons, Abstract 825.
During, M.J., Freese, A., Sorgi, F.L., Huang, L., Bilaniuk, L., Wang, Z., Mayes, L.C.,
Seashore, M.R., Mee, E., Leone, P. (1998): Intraventricular Delivery for Gene Therapy
in the Fatal, Pediatric Neurogenetic Disorder, Canavan Disease. Annual Meeting of the
American Association of Neurological Surgeons, Abstract 821.
During, M.J., Freese, A., Woodgate, A.M., Lipski, J., Young, D., Xu, R. (1998): Transfer
of the c-Jun Gene into PC12 Cells Induces Differentiation into a Neuronal-like
Phenotype. Annual Meeting of the American Association of Neurological Surgeons,
Abstract 1351.
During, M.J., Dragunow, M., Woodgate, A.M., Xu, R., Freese, A. (1998): The
Phosphorylated State of c-Jun Following Okadaic Acid Induced Apoptosis and Nerve
Growth Factor-Induced Sprouting in PC12 Cells. Annual Meeting of the American
Association of Neurological Surgeons, Abstract 1143.
Simeone, F.A., Freese, A. (1998): The opportunity costs of training to become a neurosurgeon: relevance for the expectation of appropriate compensation. Annual Meeting of
the American Association of Neurological Surgeons, Abstract 726.
Freese, A. (1998): Prospects of Gene therapy Approaches to Neuromodulation. 4th
International Congress of the International Neuromodulation Society.
Leone, P., Duncan, C., Barolat, G., Freese, A., Seashore, M., Sorge, F., Cherniske, E.,
Janson, C.G., During, M.J. (1998): Gene Therapy of Canavan Disease uisng
LPD/pAAV-ASPA: A Phase 1 Study. Proceedings 28th Annual Meeting, Society for
Neuroscience, Abstract 405.4.
Simeone, F.A., Freese, A. (1999): The Devaluation of Neurosurgical Procedures by
Managed Care and the Relevance of the Consumer Price Index over the Past Decade.
Annual Meeting of the American Association of Neurological Surgeons, Abstract 752.
Abbey, M.V., Freese, A., Bagasra, O., O’Connor, W.M., Memoli, M., Van Bockstaele, E.,
O’Connor, M.J. (1999): In Situ rtPCR: A Novel Approach towards Evaluating Gene
Expression in Human Brain Tissue. Annual Meeting of the American Association of
Neurological Surgeons, Abstract 1352.
15
Publications, continued:
Abstracts, continued:
McPhee, S.J., Fenu.S., Xu, R., Mastakov, M., Fan, X, Freese, A., During, M.J., Leone, P.
(1999): In Vivo Analysis of Tyrosine Hydroxylase Expression Cassettes in the 6-OHDA
Parkinsonian Rat Model Using AAV Vectors: A Repeated Injection Paradigm.
Proceedings 2nd Annual Meeting of the American Society of Gene Therapy Abstract
200.
Harrop, J., Poulsen, D.J., Maragakis, N.J., Xiao, W., Liu, Y., Luo, J., Rothstein, J.D.,
Freese, A., During, M.J. (2000): Transduction of Neurons and Astrocytes within the Rat
Spinal Cord using Recombinant AAV-2 and Pseudotyped AAV-5. Proceedings 30th
Annual Meeting, Society for Neuroscience, Abstract 259.7
Harrop, J.S., Poulsen, D., Maragakis, N., Xiao, W., Liu, Y., Liu, J., Rothstein, J., Freese,
A., During, M. (2000): Use of a Gene Therapy Vector (recombinant AAV) to Transduce
Neurons and Astrocytes within the Rat Spinal Cord Parenchyma. Annual Meeting of the
Congress of Neurological Surgeons, Abstract 279.
Leone, P., Freese, A., Latsko, M., McPhee, S., During, M.J., Janson, C.G. (2001):
Comparison of Viral and Non-Viral Vectors for Gene Therapy of Canavan Disease.
Proceedings of the European Metabolic Group Meeting, Amsterdam.
Liouterman, L., During, M.J., McPhee, S.W.J., Freese, A., Janson, C.G., Horst, R., Peschle,
C., Valtieri, M., Leone, P. (2001): Transplantation of Human Hematopoeitic Stem Cells
into Rat Brain: Analysis of Cell Survival and Differentiation. Proceedings 31st Annual
Meeting, Society for Neuroscience, Abstract 405.4.
Leone, P., Latsko, M., Haselgrove, J., McPhee, S.W.J., Janson, C.G., Jiao, X.Y.,
Liouterman, L., Francis, J., Young, D., Lawlor, P.A., Fitzsimons, H., Raniga, S.,
Bilaniuk, L, Wang, Z., Grant, M., Liu, Y., During, M.J., Freese, A. (2001): Gene
Therapy of Canavan Disease using AAV Vectors: A Phase 1 Clinical Trial. Proceedings
31st Annual Meeting, Society for Neuroscience.
Freese, A., Latsko, M., McPhee, S., Janson, C., Bilaniak, L., During, M., Leone, P., (2002):
Adenoassociated Virus Vector Gene Transfer into the Human Brain: A Phase1 Trial for
Patients with Canavan Disease. Annual Meeting of the American Association of
Neurological Surgeons, Abstract 710.
Leone, P., McPhee, S.W.J., Janson, C.G., Liouterman, L., Freese, A. (2002): Brain Gene
Transfer using AAV Vectors in the Canavan (Tremor) Rat Model and in Children
Affected by Canavan Disease: Targeted Development of Preclinical and Clinical
Studies. XIVth International Workshop on Genetic Systems in the Rat (Kyoto, Japan).
Freese, A., Liouterman, Liouterman, L., During, M., McPhee, S., Janson, C., Leone, P.
(2002): Transplantation of Human Hematopoeitic Stem Cells into Rat Brain; Analysis
of Cell Survival and Differentiation. Annual Meeting of the American Association of
Neurological Surgeons, Abstract 1132.
Harrop, J., Poulson, D., Darling, M., Freese, A., Maragakis, N., Rothstein, J. (2002):
Recombinant AAV Transduces Neurons and Astrocytes within the Rat Spinal Cord.
Annual Meeting of the American Associations of Neurological Surgeons, Abstract 768.
Leone, P., Janson, C.G., Freese, A., Samulski, J., Haselgrove, J. Wang, D.J., Bilaniuk, L.
(2002): Terapia Genica Nei Pazienti con Malattia Metabolica: Il Modello della Malattia
di Canavan. Milanopediatria 2002 (Milan, Italy).
16
Publications, continued:
Abstracts, continued:
Ohlfest, J., Demorest, Z., Motooka, Y., Oh, S., Chen, E., Scappaticci, F., Ekker, S., Low,
W., Freese, A. (2005): Combinatorial Antiangiogenic Gene Therapy Causes Tumor
Regression and Improves Survival in Mice Bearing Intracranial Human Glioblastoma by
Nonviral Gene transfer Using the Sleeping Beauty Transposon, American Society for
Gene Therapy, accepted for a platform presentation; Abstract 445;
Freese, A., Ohlfest, J.R., Demorest, Z.L., Motooka, Y., Vengco, I., Oh, S., Chen, E.,
Scappaticci, F.A., Ekker, S.E., Low, W.C., Largaespada, D.A. (2005): Combinatorial
Antiangiogenic Gene Therapy by Nonviral Gene Transfer Using the Sleeping Beauty
Transposon Causes Tumor Regression and Improves Survival in Mice Bearing
Intracranial Human Glioblastoma, Neurosurgical Society of America, Annual Meeting.
Ohlfest, J.R., Low, W.C., Demorest, Z.L., Largaespada, D.A., Freese, A. (2005): Nonviral
Gene Transfer to Neural Progenitor-Like Cells in the Subventricular Zone of the Adult
and Neonatal Mouse Brain with the Sleeping Beauty Transposon. Congress of
Neurological Surgeons Annual Meeting
Ohlfest, J.R., Largaespada, D.A., Low, W.C., Demorest, Z.L., Freese, A. (2005):
Combinatorial Antiangiogenic Gene Therapy by Nonviral Gene Transfer Using the
Sleeping Beauty Transposon Causes Tumor Regression and Improves Survival in Mice
Bearing Intracranial Human Glioblastoma. Congress of Neurological Surgeons Annual
Meeting
Demorest, Z.L., Low, W.C., Ohlfest, J.W., Freese, A. (2006): Long term Gene Expression
in the CNS of Neonatal Mice by Non-viral Gene Transfer Using the Sleeping Beauty
Transposon System. Annual Meeting of the American Association of Neurological
Surgeons, Abstract 1078
Oh., S., Low, W., Vengco, I., Ohlfest, J.W., Freese, A. (2006): Evaluation of the Efficacy
and Acute Toxicity of non-viral Gene Transfer in the Canine Brain. Annual Meeting of
the American Association of Neurological Surgeons, Abstract 1086
Demorest, Z.L., Vengco., I., Freese, A., Ohlfest, J.W. (2006): Nonviral Gene Transfer to
Neural Progenitor-like Cells in the Subventricular Zone of the Adult Mouse Brain with
the Sleeping Beauty Transposon. Annual Meeting of the American Association of
Neurological Surgeons, Abstract 1079.
Vengco, I., Ohlfest, J.W., Freese, A. (2006): Nonviral Gene Transfer to Cultured Pituitary
Adenoma Cells: Suppression of Growth Hormone Secretion with a Somatostatin
Vector. Annual Meeting of the American Association of Neurological Surgeons,
Abstract 1413
Ohlfest, J.W., Vengco, I., Chen, W., Low, W.C., Freese, A. (2006): Establishment of a
Breast Cancer Metastatic Model that is Rapidly Imaged and Quantified in Rodents.
Annual Meeting of the American Association of Neurological Surgeons, Abstract 1416.
Wu, A., Demorest, Z.L., Vengco, I., Chen, W., Low, W., Freese, A., Ohlfest, J.W (2006):
Combination of Sleeping Beauty-mediated INF-gamma Gene Transfer with CpG
Oligodeoxynucleotides Provides Long-Term Survival of Intracranial Glioblastoma in
Mice. American Society of Gene Therapy.
Demorest, Z.L., Low, W.C., Freese, A., Ohlfest, J. (2006): Non-viral Gene Transfer using
the Sleeping Beauty Transposon for Long-term Gene Expression in the CNS of
Neonatal Mice. American Society of Gene Therapy
Publications, continued:
17
Book Chapters, Books and Special Journals:
Freese, A., Thilly, W.G. (eds). (1988): Biotechnology Processing: Human Serum Albumin
Production, Applied Biology Reviews Series, vol. 1, Massachusetts Institute of
Technology, Cambridge, MA.
also co-authored the following chapters in the above book:
Chapter 2: ‘Human Serum Albumin: Properties and Applications’: Freese, A.,
McCafferty, F., Schaecter, J.,Van Amsterdam, J., de Moreas, C.A., Connors, N.C.,
Wu, D.Y., Kim, S.K., Chang, M., Weist, J.;
Chapter 6: ‘Mammalian Cell Technology’: Wu, D.Y., Kim, S.K., Chang, M., Weist, J.,
Freese, A.;
Chapter 7: ‘The Development of a Transgenic Chicken’: Donahue, B., Reynolds, C.,
Freese, A.
Sabel, B.S., Freese, A., During, M.J. (1990): Controlled-Release Dopamine Polymers as a
Novel Approach to the Treatment of Parkinson's Disease. Parkinson's Disease,
Advances in Neurology, (Streifler, M.B. et. al., eds), Raven Press, pp. 521-526.
During, M.J., Heyes, M.P., Freese, A., Swartz, K.J., Matson, W.R., Markey, S.P., Martin,
J.B., Roth, R.H. (1991): Indolic and Kynurenine Pathway Metabolites of Tryptophan in
Rat Brain: Effects of Precursor Availability on In Vivo Release. Tryptophan Research
(Schwarcz, R., Young, S.N., Brown, R.R., eds.), Plenum Press, pp. 535-539.
Vecsei, L, Freese, A., Swartz, K.J., Beal, M.F. (eds., 1992): Neurological Disorders: Novel
Experimental and Therapeutic Strategies. Ellis Horwood, Simon and Schuster
International Group, Hemel Hempstead, Herts, England.
Freese, A., Flamm, E.S., Cooperman, B.S., Wilson, J.M. (eds., 1995): Proceedings of the
International Conference on Gene Therapy for CNS Disorders. CME Office, University
of Pennsylvania, Philadelphia, PA.
Freese, A. (guest editor, 1997): Gene Therapy for Parkinson's Disease: Rationale, Prospects
and Limitations. Experimental Neurology, special issue, vol. 144, number 1.
Freese, A. (1999): Restorative Gene Therapy Approaches to Parkinson’s Disease.
Parkinson’s Disease and Parkinsonian Syndromes. (Stern, M.B., Hurtig, H.I. eds.).
W.B. Saunders Co., Philadelphia, PA, pp. 537-548.
Freese, A., Leone, P., Barolat, G., During, M.J. (1999): Genetic Intervention in Children
with Canavan Disease: A Model for Gene Therapy of Neurometabolic Disorders.
Neuronal Precursor Cell Biology and Application for Treatment of Inborn Error of
Metabolism. (Sakuragawa, N. ed). National Center of Neurology and Psychiatry,
Tokyo, Japan pp. 216-221.
Freese, A. (1999): Gene Therapy Approaches to Parkinson's Disease. Movement Disorder
Surgery (Lozano, A.M., ed). Karger, Basel, vol 15 pp. 381-394.
Marcotte, P., Freese, A. (2001): Spinal Injury, in The Intensive Care Unit Manual (Lanken,
P.N., ed.), W.B. Saunders Co., Philadelphia, pp.1077-1084.
Freese, A., Simeone, F.A., Leone, P., and Janson, C. (2005): Principles of Molecular
Neurosurgery. (in Lunsford, L.D. ed, Progress in Neurological Surgery, series) Karger
Medical & Scientific Publishers: New York, (a 660 page volume).
Publications, continued:
18
Book Chapters, Books and Special Journals, continued:
Marcotte, P., Freese, A., and. Samadani, U., (2014): Intensive Care Implications of Spinal
Cord Injury, in The Intensive Care Unit Manual (Lanken, P.N., ed.), Elsevier/Saunders
Philadelphia, pp. 921-927.
Freese, A., et.al. (eds., 2014): From Molecule to Man: The Biological Basis of Spine
Surgery (a 24 chapter book), in preparation.
Theses:
B.A. Honors Thesis, Harvard University, Department of Biochemical Sciences: The Effects
of Coprostanol and Other Related Sterols on the Growth and Membranes of
Mycoplasma capricolum, Thesis Advisor: Professor Konrad Bloch, Ph.D., Harvard
University (1981).
M.D. Honors Thesis, Harvard Medical School, Division of Health Sciences and
Technology: Drug and Gene Delivery into the Central Nervous System, Thesis Advisor:
Robert Langer,Sc.D., Massachusetts Institute of Technology (1990).
Ph.D. Thesis, Massachusetts Institute of Technology, Division of Health Sciences and
Technology: Excitotoxic Mechanisms in Huntington's Disease, Thesis Advisors: Joseph
B. Martin, M.D., Ph.D. and Marian DiFiglia, Ph.D., Harvard Medical School and
Massachusetts Institute of Technology (1992).
Patents and Invention Disclosures:
Sabel, B.A., Freese, A., Saltzman, W.M., Langer, R. (1989): Controlled Drug Delivery
System for the Treatment of Neural Disorders. Patent Number 4,883,666; Date of
Patent: Nov. 28, 1989, U.S. Department of Commerce.
Sabel, B.A., Freese, A., Langer, R. (1992): Extended Drug Delivery of Small, Water
Soluble Molecules. Patent Number 5,114,719; Date of Patent: May 19, 1992, U.S.
Department of Commerce.
Sabel, B.A., Freese, A., Saltzman W.M., Langer R.S. (1993): Controlled Drug Delivery
System for Treatment of Neural Disorders. European Patent Number 88106935.5,
Patent Issued.
Sabel, B.A., Freese, A. (1993): Extended Drug Delivery of Small, Water-Soluble
Molecules. European Patent Number 90116768.4, Patent issued.
Sabel, B.A., Freese, A., Saltzman, W.M., During, M.J. (1997): Polymeric Device for
Controlled Drug Delivery to the CNS; Patent Number 5,601,835; Date of Patent: Feb.
11, 1997, U.S. Department of Commerce.
Beal, M.F., Freese, A., During, M.J., Swartz, K.J. : (2001): Treatment of Neurological
Disease by Increasing Brain Concentrations of Kynurenic Acid, Patent Number
6,265,442; Date of Patent: July 24, 2001, U.S. Department of Commerce.
Freese, A.,. (2012): Adjustable cervical plate, Patent Application Number W02012088095,
patent pending
Patents and Invention Disclosures, continued:
19
Freese, A., (2012): Posterior Spine Attachment Device for Hardware and Paraspinal
Musculature, U.S. Patent Application, No. 13/961,355
Freese, A., Alutis, J., (2013): Disposable Absorbent Liquid Impermeable Coverings, U.S.
Patent Application, No. 13/935,346
Freese, A. (2014): Modular Spinal Fusion Containment System, Patent Application
pending
Seminars and Presentations:
September, 1986: ‘Phosphatidylcholine Turnover in a Neural Tumor Cell Line’, Annual
Harvard Medical School M.D., Ph.D. Program Retreat, Marine Biological Laboratories,
Woods Hole, MA.
April, 1987: ‘Safety Issues Relating to Aspartame Consumption’, presented at the Case
Report on Phenylalanine Production (for the Synthesis of Aspartame), to Industry and
University Representatives, Dept. Applied Biological Sciences, Massachusetts Institute
of Technology, Cambridge, MA.
May, 1987: ‘Therapeutic Alternatives to Tissue Plasminogen Activator’, Summary
Perspective on Tissue Plasminogen Activator, presented at the Case Report on Tissue
Plasminogen Activator, to Industry and University Representatives, Dept. Applied
Biological Sciences, Massachusetts Institute of Technology, Cambridge, MA.
August, 1987: ‘Industrial Scale Production of Human Serum Albumin through the
Development of a Transgenic Chicken’, presented with Prof. W.G. Thilly to Campbell
Soup Co., sponsored by the MIT Industrial Liaison Program, Cambridge, MA.
November, 1987: ‘Towards a Tissue Culture Model for Huntington's Disease’, Neurology
Research Seminar Series, Dept. Neurology, Mass. General Hospital, Boston, MA.
March, 1988: ‘Intrastriatal Quinolinic Acid Levels following Tryptophan Administration:
Pathogenetic Link to Huntington's Disease?’, Neurology Research Seminar Series,
Massachusetts General Hospital, Boston, MA.
June, 1988: ‘Drug Delivery Systems for Neurological Disorders’, University/Incubator Spin
Off Companies Conference, Westin Hotel, Boston, MA, hosted by the MIT Office of
Technology Licensing.
October, 1988: ‘Characterization and Mechanism of Glutamate Neurotoxicity in Primary
Striatal Cultures’, Whitehead Institute, Massachusetts Institute of Technology,
Cambridge, MA.
October, 1989: ‘Excitotoxic Mechanisms in Huntington's Disease and the Kynurenine
Pathway’, Massachusetts Institutes of Technology, Division of Health Sciences and
Technology, Cambridge, MA.
April, 1991: ‘Brain Tissue Transplantation’, Department of Surgery, University of
Pennsylvania, Philadelphia, PA.
November, 1991: ‘Excitotoxic Mechanisms in Huntington's Disease' Ph.D. Thesis Defense,
Massachusetts Institute of Technology, Cambridge, MA.
November, 1992: 'Novel Therapeutic Approaches to Parkinson's Disease: Drug and Gene
Delivery Systems’, Grand Rounds, Departments of Neurology and Neurosurgery,
University of Pennsylvania, Philadelphia, PA.
Seminars and Presentations, continued:
20
November, 1992: ‘Spinal Epidural Abscesses’, Department of Medicine, University of
Pennsylvania, Philadelphia, PA.
March, 1993: ‘Neurosurgical Approaches to Parkinson’s Disease: Past, Present and Future’,
Surgical Grand Rounds, Graduate Hospital, Philadelphia, PA.
November, 1993: ‘Pharmacology of the Kynurenenine Pathway: Endogenous
Neuroprotection’, Wyeth Ayerst Laboratories, Radnor, PA.
March, 1993: ‘Neurosurgical Approaches to Parkinson’s Disease: Past, Present and Future’,
Surgical Grand Rounds, Graduate Hospital, Philadelphia, PA.
February, 1994: ‘Gene Transfer into the CNS with Modified Herpes Vectors’, Wistar
Institute, Philadelphia, PA.
April, 1994: ‘Viral Vector Based Gene Delivery into the Brain’, Section on Functional and
Stereotactic Surgery, American Association for Neurological Surgeons, San Diego, CA.
April, 1994: ‘Molecular Biology Approaches to Studying Neurological Disorders’ Bockus
Research Laboratories, Philadelphia, PA.
December, 1994: ‘Gene Therapy Approaches to CNS Disorders’, START Technology
Partnership, Philadelphia, PA.
April, 1994: ‘Prospects for In Vivo Gene Therapy for Parkinson's Disease’, Sandoz, Inc.,
(presentation at Graduate Hospital, Philadelphia, PA)
June, 1995: ‘Gene Therapy Approaches to Pituitary Adenomas’; presentation at the
International Conference on Gene Therapy for CNS Disorders, Philadelphia, PA.
October, 1995: ‘Gene Transfer into Human Hippocampal Tissue using an Adeno-associated
Virus Vector: Prospects for Gene Therapy in Focal Epilepsy’; presentation at The
Annual Meeting of the Congress of Neurosurgical Surgeons, San Francisco, CA.
January, 1996: ‘Modulation of Dopamine Systems in the Central Nervous System: Gene
Therapy Approaches,’ Institute for Human Gene Therapy, University of Pennsylvania,
Genetics Affinity Group, Philadelphia, PA.
January, 1996: ‘Gene Therapy Approaches to Pituitary Adenomas’, the Brain Tumor Group,
Wistar Institute, Philadelphia, PA.
March, 1996: ‘Clinical Implications of Genetic Modulation of CNS Dopamine Systems’,
First Annual Ernst Freese Memorial Lecture; National Center for Human Genome
Research and National Institutes of Neurological Disorders and Stroke, National
Institutes of Health, Bethesda, MD.
April, 1996: ‘Overview of Gene Therapy for Parkinson's Disease’, The 1st Meeting of the
Parkinson's Disease Gene Therapy Consortium, Washington, D.C.
April, 1996: ‘Clinical Implications of Genetic Modulation of CNS Dopamine Systems’,
Neurosurgery Grand Rounds, University of Iowa School of Medicine, Iowa City, IA.
April, 1996: Discussant on ‘Gene Therapy for Brain Tumors by Controlled Expression of
Interleukin-lß-Converting Enzyme’, Annual Meeting of the American Association of
Neurological Surgeons, Minneapolis, MN.
April, 1996: ‘Adenovirus Vector-Mediated Delivery of the Tyrosine Hydroxylase Gene into
Striatal Cells: Implications for Gene Therapy in Parkinson's Disease’, presentation at the
Annual Meeting of the American Association of Neurological Surgeons, Minneapolis,
MN.
December, 1996: ‘Prospects for Restorative Molecular Neurosurgery’, Grand Rounds,
Department of Neurosurgery, Washington University, St. Louis, MO.
Seminars and Presentations, continued:
21
February, 1997: ‘Restorative Molecular Neurosurgery: Prospects and Limitations’, Grand
Rounds, Department of Neurosurgery, University of California, San Francisco, CA;
April, 1997: ‘A Historical Perspective on Gene Therapy: Implications for Molecular
Neurosurgery’, Annual Meeting of the American Association of Neurological Surgeons,
Denver, CO.
July, 1997: ‘Gene Therapy for Neurological Disorders’, Davis Biotechnology Associates,
Los Angeles, CA.
September, 1997: ‘The Present and Future of Gene Therapy for Neurological Disorders’,
platform presentation at the Pennsylvania Neurosurgical Society, Hershey, PA.
April, 1998: ‘Phenotypic Recovery in Parkinsonian Rats: Relationship Between Number of
Transduced Cells and Behavior Using an Adenoviral Vector Expressing Tyrosine
Hydroxylase’, Annual Meeting of the American Association of Neurological Surgeons,
Philadelphia, PA.
April, 1998: ‘Intraventricular Delivery for Gene Therapy in the Fatal, Pediatric
Neurogenetic Disorder, Canavan Disease’, Annual Meeting of the American
Association of Neurological Surgeons, Philadelphia, PA.
September, 1998: ‘Prospects of Gene Therapy Approaches to Neuromodulation’, 4th
International Congress of the International Neuromodulation Society, Lucerne,
Switzerland.
September, 1998: ‘Gene Therapy of CNS Diseases,’ Progen, Inc., Heidelberg, Germany.
November, 1998: ‘What’s Ahead: Potential for Gene Therapy of Pituitary Adenomas’, The
Atlantic Seaboard Pituitary Conference, Philadelphia, PA.
December, 1998: ‘The Future of Gene Therapy’, The 10th Pan-Philadelphia Neurosurgical
Conference, Philadelphia, PA.
December, 1998: ‘Gene Therapy for Neurosurgical Disorders’, Surgical Grand Rounds,
Thomas Jefferson University, Philadelphia, PA.
December, 1998: ‘Prospects for Endovascular Delivery of Gene Therapy to the Brain’,
Cordis Endovascular, Miami Lakes, FL.
January, 1999: ‘Gene Therapy for Neurological Disorders: Science Fact, not Fiction’,
Neurosurgery Grand Rounds, Temple University, Philadelphia, PA.
January, 1999: ‘Gene Therapy for Neurosurgery’, Grand Rounds, Department of Surgery,
Graduate Hospital/Hahnemann University, Philadelphia, PA.
January, 1999: ‘Stereotactic Approaches to Gene Therapy of CNS Disorders’, Radionics,
Inc., Burlington, MA.
February, 1999: ‘Genetic Intervention in Children with Canavan Disease: A Model for Gene
Therapy of Neurometabolic Disorders’, International Workshop on Neuronal Precursor
Cell Biology and Application for Treatment of Inborn Error of Metabolism, Tokyo,
Japan.
February, 1999: ‘Gene Therapy of CNS Disorders’, Neurosurgery Grand Rounds, Sinjeako
University, Tokyo, Japan.
March, 1999: ‘Gene Therapy Approaches to Neurological Disease’, Presentation to
Genzyme, Inc., Cambridge, MA.
May, 1999: ‘Gene Therapy for Neurological Disorders’, Neurology Grand Rounds, Thomas
Jefferson University, Philadelphia, PA.
July, 1999: 'Gene Therapy for Neurosurgical Diseases', Neurology/Neurosurgery Grand
Rounds, Medical College of Wisconsin, Milwaukee, WI.
Seminars and Presentations, continued:
22
November, 1999: 'Prospects for Genetic Intervention in Neurological Diseases'
Neurosurgery Grand Rounds, Medical University of South Carolina, Charleston, SC
December, 1999: 'Gene Therapy in Canavan Disease' The 11th Pan Philadelphia
Neurosurgical Conference, Philadelphia, PA.
February, 2000: 'Gene Therapy for Neurosurgical Diseases - Science Fiction or Science
Fact' Neurosurgery Grand Rounds, Medical University of South Carolina, Charleston,
SC
December, 2000: 'Molecular Neurosurgery: Science Fiction or Science Fact?', Neurosurgery
Grand Rounds and Visiting Professor, SUNY, Syracuse
February, 2001: 'Gene Therapy for Neurosurgical Diseases', Neurosurgery Grand Rounds,
Thomas Jefferson University, Philadelphia, PA
March, 2001: 'Gene Therapy for Neurosurgical Diseases: Science Fact vs. Science Fiction',
Neurosurgery Grand Rounds, Henry Ford Hospital, Detroit, MI
April 2002: 'Gene Therapy for Canavan Disease with an AAV Vector. American
Association of Neurologic Surgeons, Chicago, IL
May 2002: 'Gene Therapy for Spinal Disorders Sofamor Danek Think Tank, Amelia Island,
FL
November, 2002: ‘A Neurosurgeon Wandering Through the Fields of Gene Therapy:
Lessons Learned’, University of North Carolina, Chapel Hill, Gene Therapy Center and
Department of Neurosurgery, Grand Rounds
February, 2003: 'Disk Replacement Surgery, Indications vs. Hype' Grand Rounds, Thomas
Jefferson University, Philadelphia, PA
August, 2003: ‘Gene Therapy of Neurological Disorders’, University of Heidelberg,
Heidelberg, Germany, scheduled presentation.
September, 2003: ‘Gene Therapy and Cervical Spinal Disorders’, Harvard Medical School ,
Cervical Think Tank, Boston MA
December, 2003: ‘A Neurosurgeon’s Travels in Gene Therapy: It Doesn’t Take a Gene
Therapist to do Brain Surgery.’Grand Rounds, University of Minnesota (Minneapolis),
Department of Neurosurgery, Minneapolis, MN
February, 2004: ‘Disk Replacement Surgery: An Overview’, Grand Rounds, University of
Pennsylvania Department of Orthopaedic Surgery, Philadelphia, PA.
October, 2004: ‘Gene Therapy and Canavan Disease’, Keynote Speaker at annual Canavan
Foundation Gala, Chicago, IL
November, 2004: ‘Gene and Cellular Therapy for Neurological Diseases’, Minnesota
Medical Foundation, Minneapolis, MN
March, 2005: ‘Prospects for Gene Therapy for Neurological Diseases’, University of
Minnesota and Medtronic Neuroscience Symposium, Fridley, MN
March, 2005: ‘Fusions and Their Alternatives: Making the Right Call’, 20th Annual
Workers’ Compensation Institute, Minneapolis, MN
April, 2005: ‘The Future of Biologics in Spine Surgery’, Annual Meeting, Synthes Spine,
Hollywood, FL
April, 2005: ‘A Neurosurgeon’s Experience in Gene Therapy: Implications for Molecular
Neurosurgery’, Department of Neuroscience, University of Minnesota, Minneapolis,
MN
May, 2005: ‘The CNS Gene Therapy Initiative’, Fairview Foundation Annual Meeting,
Keynote Speaker, Minneapolis, MN
Seminars and Presentations, continued:
23
June, 2005: ‘Novel Combinatorial Gene Therapy Approaches to Malignant Brain Tumors’,
presentation at the Neurosurgical Society of America, Orlando, FL
August, 2005: ‘Lumbar Spine Fusion Surgery: Options and Outcomes’, Workers
Compensation Board, Evalumed, Minneapolis, MN
August, 2005: ‘Molecular Neurosurgery: Gene Therapy Approaches to Neurosurgical
Diseases’, Neurosurgery Grand Rounds, Yale University, New Haven, CT.
September, 2005: ‘Molecular Neurosurgery: The Road to the Future’, Grand Rounds,
University of Chicago, Chicago, IL.
October, 2005: ‘Combinatorial Antiangiogenic Gene Therapy by Nonviral Gene Transfer
Using the Sleeping Beauty Transposon Causes Tumor Regression and Improves
Survival in Mice Bearing Intracranial Human Glioblastoma’, scheduled presentation for
the Congress of Neurological Surgeons, Boston, MA.
January, 2006: ‘The Advent of Molecular Neurosurgery’, Grand Rounds, Texas A&M
School of Medicine/Scott and White Clinic, Temple, TX
May, 2006: ‘Molecular Approaches to Neurosurgical Diseases’, Grand Rounds, University
of South Carolina School of Medicine, Dept. Surgery, Columbia, SC
December, 2006: ‘Spinal Cord Injury: An Overview’, Combined Graduate Program in
Neurosciences Lecture for University of South Carolina School of Medicine and the
Medical University of South Carolina, Charleston.
2008-current: numerous Chester and Philadelphia County presentations on
Brandywine/Commonwealth Spine Center to community organizations, YMCAs,
churches, Senior Circle events, county fairs
24